This is the moment... "People know the price of everything, but the value of nothing…"
The beta males are consumed by CZO's current stock price. Every time one sells they panic more; but what is the potential value of what has been created? This moment is for the person of vision. The pipeline sits before key value defining catalysts. The timeline to the outcomes, for better or worse, has never been more certain.
The base business may need until Q3 to get fully back on track but the pipeline is on the goal line of major catalysts and the stock price had been discounted. Negotiating a PGX deal could have some play until the current PGX scale-up is fully commissioned and proven in the first half of 2024 but PGX plant construction is expected complete by year-end. Some time savings may have also been identified by the new VP of Technical Operations though no specifics have been provided.
1) Enrollment Of The Avenanthramide Clinical Trial Is About To Begin:
“The commencement of this study represents a noteworthy milestone in the development of our avenanthramide program and could be the most significant transformational step we have taken to date in executing on our strategy to expand Ceapro’s business model towards becoming a biopharmaceutical company with the potential to provide an innovative product into very large markets." Gilles Gagnon "Chronic low-grade inflammation has been identified as a major contributor in the development of atherosclerosis. Nuclear Factor-κappa B (NF-κB) is a critical transcription factors family of the inflammatory pathway. As a major catalytic subunit of the IKK complex, IκB kinase β (IKKβ) drives canonical activation of NF-κB and is implicated in the link between inflammation and atherosclerosis, making it a promising therapeutic target."
Anti-inflammatory therapy of atherosclerosis: focusing on IKKβ | Journal of Inflammation | Full Text (biomedcentral.com) Avenanthramide Are Potent Inhibitors:
"These data indicate that Avns are potent inhibitors of NFκB-mediated inflammatory response due to the downregulation of IKKβ activity in C2C12 cells." Anti-inflammatory effect of avenanthramides via NF-κB pathways in C2C12 skeletal muscle cells - ScienceDirect 2) 'Go / No Go' Clinical Trial Decision For Fibrosis Expected In Q3:
“Until now, we have had very limited treatment options for fibrotic lung disease since approved medications can only slow down the progression of the disease. We are very encouraged by the results from this study showing that PGX-YBG has the ability of reprogramming macrophages to prevent fibrogenesis in mice. If these results are replicated in human trials, this treatment approach could profoundly change the landscape of fibrotic lung disease therapeutics,” added Dr. Martin Kolb, a respected Pulmonologist and Professor of Medicine at McMaster University.
3) PGX Scale-Up Construction Expected By Year-End: "...the installation testing and commissioning of the PGX-100 in the AFDP building which is anticipated to occur in the first half of 2024." CZO new release Gilles noteed discussions are currently underway with serious companies concerning the licensing of one PGX-CoQ10 complex to a neutraceutical company. He states CoQ10 is a $4 billion market and that companies understand bioavailability as CZO's unique selling point. The YBG immune booster market is also a $1 billion opportunity. "While three global suppliers for YBG were shortlisted (from Germany, China, Brazil), one YBG feedstock material clearly outperformed all others in terms of purity, batch-to-batch consistency, heavy metal content, and available certifications (IFS, FSSC 22000, Kosher, Halal, GMO-free)." Annual Report
4) Scale-Up Of The Avenanthramide Malting Technology To Commercial-Scale Is Almost Complete:
This will allow CZO access to certain neutraceutical food and beverage markets.
5) Video Event With Dr. Li For Avenanthramide and Beta Glucan For Wound Healing:
The event will discuss the data and the next steps. CZO could have a wound healing franchise. "This is a major discovery in tissue regeneration and these results will support additional claims for commercial and new products formulated with Ceapro’s oat-based products." CZO news release
6) Potential NASDAQ Listing: "...continuing our discussions to assess different market capitalization initiatives and corporate opportunities to unlock value,” commented Gilles Gagnon, M.Sc., MBA, President and CEO." CZO news release